LINKEDIN TWITTER PATIENTS & CAREGIVERS MEDICAL PROFESSIONALS CAREERS INVESTORS ABOUT US RESEARCH PIPELINE NEWS & EVENTS CONTACT US ABOUT US Our History 2008 Agios Pharmaceuticals is founded in Cambridge, Mass., to unlock a new field of discovery in cellular metabolism 2009 Labs opened in January 2009 Agios groundbreaking research establishes for the first time that the mutated metabolic gene IDH1 has novel enzyme activity consistent with an oncogene and publishes the article in Nature Continued to build the company’s research platform 2010 Entered into a global, strategic collaboration with Celgene Corporation to discover and develop novel cellular metabolism-related therapies Together with collaborators at Memorial Sloan Kettering, Agios publishes landmark paper in Cancer Cell, potentially implicating IDH mutation in a distinct mechanism of acute myeloid leukemia (AML) pathogenesis 2011 Closed a $78 million oversubscribed Series C financing Expanded research focus into rare genetic metabolic disorders Celgene exercised the option to extend the cancer metabolism research collaboration for another year 2012 Discovered the first potent inhibitors of mutant IDH that lower tumor 2-HG in vivo and published the findings in the American Chemical Society Medicinal Chemistry Letters Published article in Nature reinforcing the pathogenic role of IDH mutations in AML 2013 Initiated first clinical study of enasidenib in patients with IDH2 mutant hematologic malignancies Completed initial public offering on NASDAQ Named a Technology Pioneer by the World Economic Forum Presented the first preclinical data from Agios’ rare genetic diseases research program Science publishes back-to-back articles by Agios interrogating the roles of mutated IDH2 in leukemia and IDH1 in glioma via specific pharmacological inhibition 2014 Presented first clinical data from the enasidenib Phase 1 study Initiated the first clinical trial of Ivosidenib in patients with IDH1 mutant hematologic malignancies Initiated a second clinical study of Ivosidenib in patients with IDH mutant solid tumors Initiated first-in-human, healthy volunteer study of AG-348, Agios’ first PKR activator Initiated registration-enabling expansion cohorts in the Phase 1 study of enasidenib in IDH2 mutant hematologic malignancies Presented the first clinical data from the Phase 1 healthy volunteer study of AG-348 The FDA granted enasidenib both Fast Track and Orphan Drug Designation Celgene exercises option to license enasidenib worldwide, with Agios to co-commercialize in the U.S. 2015 The FDA granted Ivosidenib both Fast Track and Orphan Drug Designation FDA granted Orphan Drug Designation for AG-348 for the treatment of PK deficiency Initiated Phase 1 study of AG-881 in patients with advanced solid tumors with an IDH mutation Presented the first clinical data from the Phase 1 study of Ivosidenib in patients with IDH1 mutant solid tumors Initiated the Phase 3 IDHENTIFY study of enasidenib in patients with AML Initiated a Phase 1b study of enasidenib or Ivosidenib in combination with chemotherapy in patients with newly diagnosed AML Initiated a Phase 2 study of AG-348 in adult, transfusion-independent patients with PK deficiency (DRIVE-PK) 2016 Initiated a Phase 1/2 study of enasidenib or Ivosidenib in combination with VIDAZA® in patients with newly diagnosed AML Entered into a global research collaboration with Celgene focused on metabolic immuno-oncology Presented first data from the Phase 2 DRIVE-PK study of AG-348 in patients with PK deficiency Initiated a Phase 3 study of ivosidenib in cholangiocarcinoma Filed a New Drug Application, along with Celgene, with the U.S. FDA for enasidenib 2017 Received FDA approval of the first product from our research platform, which is co-developed and co-commercialized with Celgene Initiated the Phase 3 AGILE study of ivosidenib in frontline AML patients Filed first wholly owned New Drug Application with the U.S. FDA for ivosidenib 2018 Received FDA approval of the first wholly owned product Initiated two global pivotal trials for mitapivat in PK deficiency Initiated first clinical trial for AG-270 Submitted seventh IND for DHODH inhibitor AG-636 2019 Received sNDA for TIBSOVO® as monotherapy for newly diagnosed adult patients with IDH1 mutant AML not eligible for intensive chemotherapy Announced our first Phase 3 study, the ClarIDHy trial of TIBSOVO® in IDH1 cholangiocarcinoma, met its primary endpoint Jackie Fouse, Ph.D. named as Chief Executive Officer Opened our EU headquarters in Zug, Switzerland Published results from Phase 2 DRIVE-PK study of mitapivat in patients with PK deficiency in New England Journal of Medicine Established clinical proof-of-concept for mitapivat in non-transfusion-dependent thalassemia 2020 Established clinical proof-of-concept for mitapivat in sickle cell disease Initiated first clinical study of next-generation PKR activator AG-946 The FDA granted Orphan Drug Designation to mitapivat for the treatment of thalassemia and sickle cell disease; the EMA granted Orphan Drug Designation to mitapivat for the treatment of PK deficiency Royalty Pharma acquired rights to Agios’ royalty on IDHIFA® worldwide net sales and outstanding regulatory milestone payments for $255 million Published results from ClarIDHy Phase 3 study of ivosidenib in patients with previously treated IDH1-mutant cholangiocarcinoma in The Lancet Oncology Announced positive data from ACTIVATE Phase 3 trial of mitapivat in adults with PK deficiency who are not regularly transfused Announced agreement to sell oncology business to Servier for up to $2 billion plus royalties, enabling Agios’ new strategic, singular focus on genetically defined diseases 2021 Announced positive data from ACTIVATE-T Phase 3 trial of mitapivat in adults with PK deficiency who are regularly transfused Presented final data from ClarIDHy Phase 3 study of ivosidenib in patients with previously treated IDH1-mutant cholangiocarcinoma Filed sNDA for ivosidenib as for patients with previously treated IDH1-mutant cholangiocarcinoma Sold oncology business to Servier for up to $2 billion plus royalties Patients & Caregivers Our Commitment Investigational Medicines Clinical Trials Pyruvate Kinase Deficiency Patient Resources Medical Professionals Medical Professionals Careers Our Values Inside Agios Find a Job Benefits Commitment to Our Community Investors Overview Press Releases Events & Presentations Stock Information Financials Resources Contact Us About Us About Us Our Values Leadership Board of Directors Scientific Advisors Founders Our History Corporate Responsibility & Sustainability Research Our Research Platform Publications Pipeline Pipeline News & Events Press Releases Events & Webcasts Contact Us Contact Us © 2021 Agios, Inc. All rights reserved. Privacy Notice Cookie Preferences Copyright Info Terms of Use Compliance Sitemap Contact Us Do Not Sell My Personal Information Your Cookie Settings We use cookies and related technologies (“Cookies”) to provide services, gather information when users navigate through the sites, and to provide the best user experience when you visit our website. Some cookies are necessary for running our website while others are used for statistical purposes or for understanding usage patterns to enhance and personalize the experience. You can decline the use of non-essential cookies or decide which cookies should be allowed by changing your Cookies Settings, but please consider that some functionalities of the website may not be available based on your choices. By clicking “Accept All Cookies” you are agreeing to the placement of cookies. Privacy Notice Cookies Settings Decline Accept